Abstract HIV-infected persons who use drugs (PWUDs) are particularly vulnerable for suboptimal combination antiretroviral therapy (cART) adherence. A systematic review of interventions to improve cART adherence and virologic outcomes among HIV-infected PWUDs was conducted. Among the 45 eligible studies, randomized controlled trials suggested directly administered antiretroviral therapy, medication-assisted therapy (MAT), contingency management, and multi-component, nurse-delivered interventions provided significant improved short-term adherence and virologic outcomes, but these effects were not sustained after intervention cessation. Cohort and prospective studies suggested short-term increased cART adherence with MAT. More conclusive data regarding the efficacy on cART adherence and HIV treatment outcomes using cognitive behavioral therapy, motivational interviewing, peer-driven interventions and the integration of MAT into HIV clinical care are warranted. Of great concern was the virtual lack of interventions with sustained post-intervention adherence and virologic benefits. Future research directions, including the development of interventions that promote long-term improvements in adherence and virologic outcomes, are discussed.
Introduction
The introduction of potent, combination antiretroviral therapy (cART) beginning in the mid-1990s transformed HIV/ AIDS into a chronic condition by suppressing viral replication and restoring damaged immune systems [1] [2] [3] . Similar to the treatment of other chronic conditions, improved health outcomes among individuals with HIV are contingent on relatively stringent and high levels of adherence to cART [4] . Among the estimated 1.1 million people living with HIV/AIDS (PLWHA), only one in five has achieved virological suppression [5] . Though cART combinations differ in terms of their toxicities, potency and pharmacokinetic half-lives, resulting in differing levels of adherence to achieve viral suppression [6] [7] [8] , the success of cART, nevertheless, ultimately depends entirely on adequate adherence. Ultimately, high levels of adherence are required to robustly suppress plasma HIV RNA levels (viral load; VL) [9] , and incomplete adherence has been associated with virological failure and the potential development of antiretroviral resistance [8, [10] [11] [12] [13] [14] [15] .
A particularly vulnerable population, both with respect to high HIV rates and problematic cART adherence, are people who use drugs (PWUDs). Recent surveillance data within the US suggest that approximately 9 % of HIV diagnoses among adults and adolescents in 2010 were attributable to injection drug use [16] . In a seminal epidemiological review of HIV rates among IDUs, Mathers [17] reported HIV prevalence rates among people who inject drugs (PWIDs) as 20-40 % in five countries and over 40 % in nine, with approximately 3 million HIV-infected PWIDs worldwide. Stimulant use, such as methamphetamine, is also associated with high HIV seroconversion rates among men who have sex with men. These rates are between two and four times that of MSM who do not use this drug, presumably from engaging in concurrent drug and sexual HIV-risk behaviors [18, 19] .
HIV-infected PWUDs have reduced access to cART, initiate therapy at advanced stages of HIV infection, and are more likely to experience problematic adherence compared to those who do not use drugs [20••] . As a result, clinicians may not prescribe cART to PWUDs, particularly because of cited evidence conferring the emergence of viral resistance and the transmission of drug-resistant HIV strains among non-adherent patients [13, 21, 22] . The data among HIV-infected PWUDs, however, have not provided empiric evidence that PWUDs ultimately develop increased levels of drug-resistant strains and transmit resistant virus. HIVinfected drug users can achieve the same levels of adherence as people living with HIV/AIDS who have never used drugs [23•] . Survival among HIV-infected patients initiating cART with and without a history of injection drug use did not differ [24] , suggesting cART access is the problem. Despite this, many HIV treatment trials have excluded drug users to date for a variety of reasons that often complicate cART delivery and maintenance, including the instability resulting from recurrent drug-seeking behaviors, frequent homelessness and comorbid psychiatric illness [20••, 25, 26] .
The catalysts behind conducting this systematic review stemmed from participation in two pivotal investigations: the guidelines committee of the International Association of Physicians in AIDS Care (IAPAC) that created the first recommendations for linkage to care and cART adherence [27••] , and the Centers for Disease Control and Prevention (CDC) release of the Prevention Research Synthesis HIV Medication Adherence Review [28] . Given the international emphasis on the Seek, Test, Treat and Retain paradigm, a core component of which is adherence to cART regimens, both investigations represent a timely and crucially-needed review of the antiretroviral adherence field. Importantly, the CDC review identifies methodological limitations extant in the current research base. Some of the efficacy criteria used to evaluate the interventions were somewhat stringent, however, including an analytic sample of at least 40 participants per study arm, at least a 60 % retention rate (or medical chart recovery) for each study arm, and no evidence for negative intervention effects (in a primary or replication study) for any HIV-related behavioral or biologic outcome. Such criteria would likely not allow for the identification of promising pilot trials, which are inherently smaller in scope, or more broadly for the detection of patterns in the efficacy, or lack thereof, of different classes of interventions. Therefore, this review will adopt a broader scope.
In addition, it is arguably the case that treatments that are evaluated in populations that experience multiple medical and/or psychiatric co-morbidities have a particularly high bar to clear; adherence interventions that target HIV-infected individuals with substance use disorders (SUDs) are aiming to improve adherence behaviors (and concomitant virologic and immunologic outcomes) in the context of strongly countervailing co-morbidities. Thus, this systematic review examines both positive and negative intervention effects (and at various time points) in order to more precisely understand the mechanisms by which successful interventions target multiple morbidities.
Finally, although thorough literature reviews of adherence interventions for individuals with SUDs exist, several are older and require updating in light of recent intervention results, while others focus primarily on adherence behaviors (but not virologic and immunologic responses of the interventions; [29•, 30-38] ). As a result, this review will provide a current state of the science review.
Methods
The systematic review was conducted using PRISMA guidelines [39, 40] , including a 27-item checklist and a four-phase flow diagram.
Eligibility Criteria
Studies assessing the short-and long-term outcomes of interventions that targeted cART adherence and/or virologic and immunologic outcomes among current and/or past adult drug users were included. Given the strongly linked mediating relationship of adherence to VL [9, 41] , the authors included studies that measured either cART or virologic and immunologic outcomes or both. All types of interventions were evaluated, including medication-assisted therapy, psychosocial/behavioral, and integrated medication-assisted therapy and behavioral interventions. Apart from case series studies, almost all study designs were initially considered, including randomized clinical trials, matched studies, quasiexperimental studies, and prospective longitudinal cohorts. Studies that describe known structural impediments, such as repeated incarceration [42] and police harassment [43] , which was otherwise not subjected to an intervention, were not included. As cART did not become available until 1996 and guidelines for treatment were not available until 1997, only studies published between January 1997 and July 2011 were considered. Studies involving adolescents, children, or not published in English were not assessed. Trials that did not explicitly and clearly target PWUDs in their recruitment were not included. As such, at least 50 % of the subjects in a study must have identified as PWUDs.
All measures of adherence were recorded, including directly administered antiretroviral therapy, pill counts, electronic pill bottle caps (MEMS caps), self-reported recall (e.g., 3-day AIDS Clinical Trials Group), pharmacy refill data, and timeline follow-back method. Adherence behaviors were assessed over a wide range of timeframes, including monthly, 3-month, 6-month, and 12-month. Virologic and immunologic outcomes were typically reported as VL and CD4, respectively. Drug use (current or remote) was defined as the use of any illicit substance (heroin, cocaine, crack, opioids, methamphetamine, and marijuana) or drinking of alcohol.
Information Sources and Search
In order to minimize the bias of missed published interventions, multiple search strategies were implemented (See Fig. 1 Flow chart). Studies were identified through three methods: systematic searches of electronic databases, reviewing reports from HIV listservs, and scanning reference lists of relevant review articles. The first search strategy was applied to the electronic databases OVID, Web of Science, PubMed, GoogleScholar and SCOPUS. Multiple search terms were deployed, reflecting four categories: (1) substance abuse (i.e., alcohol, heroin, cocaine, crack, opioids, methamphetamine, marijuana), (2) medication adherence (i.e., adherence, nonadherence, compliance, noncompliance), (3) study type (i.e., randomized controlled trial, multicenter study, meta-analysis, clinical trial, case control study, cohort study, feasibility study, intervention study, pilot project, sampling study, crossover study, matched-pair analysis, cross sectional study), and (4) antiretroviral (i.e., highly active antiretroviral therapy, antiretroviral agents, combination antiretroviral therapy, anti-HIV agents). Conference posters and abstracts were excluded. Studies through July 2011 were included. In addition, various relevant HIV listservs were explored for conference abstracts after July 2010, newly published articles, and articles that had been recently submitted for publication. Various experts in the field were consulted to inquire about manuscripts that were in preparation or under review that contained relevant data for this review. Finally, the reference lists of relevant review articles that matched the above search strategy were scanned.
Study Selection
One author (MCB) screened records initially by title and abstract for eligibility. The full text of peerreviewed papers published in English were extracted and included in the systematic review if they met all five of the following criteria: (1) described an adherence-promoting intervention; (2) reported outcome data on adherence and/or viral load and/or CD4; (3) explicitly targeted PWUDs; (4) included individuals 18 years of age or older; and (5) contained a study population in which at least 50 % were substance users. Reviews were excluded themselves, but articles from the reference lists that met the above criteria were included. Another author (SK) confirmed or rejected articles based on eligibility criteria. Inter-rater agreement was high. When consensus could not be reached, the third author (FLA) reviewed the article to break the tie. If there was no consensus, authors of the original studies were contacted in order to obtain additional information to assist the third author in adjudicating differing inclusion decisions.
Data Collection Process and Data Items
Standardized data collection forms were used for extraction that included the following information: first author and date published, year of study, study design, study size, demographic characteristics, study location and setting (community, drug treatment facility, correctional facility, methadone program), type of substance abuse, inclusion criteria, description of intervention and control groups (duration, baseline n, treatment type/components), primary outcomes, end intervention effect, postintervention effect, and impact on adherence and viral load. All extracted data were initially extracted by one co-author (MCB) and then independently assessed by the other two (SK and FLA) who juxtaposed author names to avoid sample overlap between trials and to identify inconsistencies. Again, there was a high level of agreement.
At the conclusion of the data extraction process, studies were divided into three graduated tiers based on rigor of study design. Tier I consisted of randomized clinical trials while Tier II included matched studies such as prospective and retrospective cohort studies and nonrandomized clinical trials. Finally, Tier III incorporated quasi-experimental studies, for instance observational studies, pilots, feasibility studies, and clinical trials and prospective cohort studies without control arms. The three tiers were then subdivided by type of intervention (medication-assisted therapy, psychosocial/ behavioral, integrated medication-assisted therapy and behavioral, integrated medication-assisted therapy and HIV care). We focused on the measurement of intervention effects on adherence as well as virological and immunologic outcomes.
Results
Tables 1, 2 and 3 incorporate all included studies, grouped by tiers, and details relevant study characteristics based on the extraction scheme.
Medication-Assisted Therapy Interventions
There were no Tier 1 interventions solely evaluating medication-assisted therapy (MAT) to foster HIV treatment adherence among PWUD populations. Despite this, there were several good quality studies that addressed the effect of MAT on HIV treatment adherence and markers of HIV progression. Avants et al. [44] reported significant increases in self-reported medication adherence among 42 HIVinfected IDUs beginning methadone maintenance treatment (MMT), while other studies indicated that buprenorphine (BPN) maintenance treatment increased adherence to cART regimens [45] and may keep VL and CD4 relatively stable at short-term follow-up [46] .
Prospective longitudinal data confirmed findings described earlier. In a longitudinal prospective cohort of opioid dependent, HIV-infected IDUs, MMT provision was independently and significantly associated with increased adherence, more rapid uptake of cART, viral suppression and CD4 increases [47] . A 5-year longitudinal study of opioid substitution treatment (OST), including BPN and methadone, with cART experienced opioid-dependent individuals concluded that retention in OST was significantly associated with long-term virological success [48] . This association held even after adjustment for significant predictors (such as adherence) of long-term virological success.
Behavioral and Psychosocial Interventions
Directly Administered Antiretroviral Therapy (DAART)
Three independent DAART RCT trials [49] [50] [51] consistently showed significantly higher rates of cART adherence, improved virologic functioning, and increased CD4 counts among DAART participants compared to control groups at Deering [73] Social supportpeer driven short-term follow-ups. Successful virologic outcomes after DAART discontinuation, however, remain more equivocal, with some interventions demonstrating maintenance of these gains and others not. In the largest RCT, Altice et al. [49] , compared 6-month DAART to self-administered therapy (SAT) among 141 HIV-infected drug users (cocaine and/or heroin). Both for virologic and immunologic outcomes, the DAART arm was statistically superior to the SAT arm at the 6-month intervention endpoint. Similar results were seen in subgroup analyses stratifying the patients by virologic suppression at baseline. There was a trend toward greater adherence among patients receiving DAART as compared to SAT, but this did not reach statistical significance. The virological outcomes did not persist, however, over the subsequent six months of followup after DAART was terminated [52] .
Macalino et al. [50] randomized 87 HIV-infected drug users [broadly defined as heroin/cocaine/alcohol use in the past 6 months, other drug use on four or more of the last seven days, or alcohol misuse (positive response on the CAGE alcohol screening questionnaire)] to receive either modified DAART or standard of care. At the end of 3 months, DAART participants were more likely to achieve VL suppression or a >2.0 log reduction than controls, a result driven primarily by those individuals who had previously received cART. Findings for CD4 were largely consistent with the virologic outcomes: mean CD4 at month 3 was higher in the DAART than the control arm, an effect that was primarily driven by cART-experienced individuals.
One study reported favorable virologic and immunologic results as well as improvements in cART adherence in response to an intervention that formally integrated DAART into a MMT program. Berg at al. [51] compared DAART to SAT among 77 HIV-infected MMT opioid users during 24 weeks. Over the course of the trial, patients in the DAART arm consistently displayed significantly higher adherence rates than the SAT group, while VL in the DAART group decreased 0.52 log 10 copies/ml and remained stable in the SAT group. Effects were more pronounced for those demonstrating baseline detectable VL.
Follow-up of the trial indicated that benefits of DAART ceased after it was terminated [53] . Results from a post-trial cohort study of 65 individuals who had completed the initial 24-week trial suggested that after DAART ended, differences in adherence diminished by 1 month and extinguished completely by 3 months. Similarly, differences in VL between the DAART and SAT groups returned to baseline within 3 months after intervention termination, as did the proportion of DAART participants with undetectable VL within each group. Finally, a significant relationship between counseling and cART adherence was reported among a subset of individuals (n022) who received six individual counseling MI/CBT sessions over the course of a 12-month period after the 24 week DAART trial ended [54] . No significant association between cumulative adherence counseling hours and post-counseling and VL, however, was found.
Second tier data also suggest promising outcomes for DAART in improving virologic outcomes among heterogeneous populations, including African American HIVinfected PWUDs [55] , treatment-naïve HIV-infected IDUs in Italian prisons [56] , and HIV-infected cART experienced PWUDs [57] . Second and third tier data for interventions that incorporated both DAART and MMT were somewhat consistent with data from the Berg et al. [51] trial, although suggested persistence of virologic and immunologic improvements at longer-term follow-up points. A prospective observational study among MMT HIV-infected IDUs demonstrated that a majority of patients (both cART naïve and experienced) achieved maximum viral suppression as well as significant incremental mean CD4 changes from baseline over 12 months of treatment [58] . Other long term-follow-up data indicated that a significant majority of MMT patients who received DAART were more likely to exhibit VL<400 copies/ml after 24 month follow-up as compared to baseline [59] and to achieve viral suppression through 12 months than were patients in comparison groups [60] . Finally, Sorensen et al. [61] reported marginal shortterm improvements in adherence behaviors in the DAART arm compared to standard care participants, but the modest gain and group differences disappeared within one month after intervention completion. Virologic and immunologic outcomes, however, were not reported. It should be noted that it was difficult to draw conclusions from several MMT/ DAART trials (e.g., [62] ) as they reported a relatively small proportion of supervised cART doses in many patients.
Contingency Management
All three contingency management studies [63] [64] [65] converged on similar results and demonstrated short-term improvements in cART adherence, but none showed persistence after vouchers were discontinued. Petry et al. [63] compared weekly CM or 12 Steps (TS) groups for 24 weeks among 170 HIV-infected patients with cocaine or opioid use disorders. From pre-to post-treatment, CM participants showed greater reductions in VL than TS participants, maintaining significant effects after controlling for duration and study group of interaction, with VL reduction among CM subjects and VL increase among TS participants. These effects, however, were not maintained throughout the 12-month follow-up period.
Rigsby et al. [64] randomized 55 HIV-infected subjects (the majority of whom had histories of heroin or cocaine use) to 4 weekly sessions of either nondirective inquiries about adherence (control group), cue-dose training (CD), or cue-dose training combined with cash reinforcement for correctly timed bottle opening (CD-CR). Results indicated significant improvement in adherence for the CD-CR but not for the CD group (as compared to the control group) during the active training period. By using week 4 adherence as a covariate, however, there was a significant decrease in adherence over time in the CD-CR group. Mean VL change from baseline through 12-week follow-up was not statistically significantly different between each of the training groups and the control group.
Rosen et al. [65] built on the earlier Rigsby et al. [64] trial by lengthening the number of weeks individuals received treatment. Within the context of this new trial, 56 HIVinfected participants with SUDs and suboptimal adherence to cART were randomly assigned to 16 weeks of weekly CM-based counseling or supportive counseling, followed by 16 additional weeks of data collection and adherence feedback to providers. Mean adherence to cART was significantly increased relative to the supportive counseling group during the 16-week treatment phase. Though virologic outcomes were also improved in the immediate post-intervention aftermath for the CM group, differences between groups on adherence and VL outcomes were no longer significantly different after 16 weeks of observation.
Counseling Using Motivational Interviewing (MI) and/or Cognitive-Behavioral Treatment (CBT)
One RCT and two pilot trials using MI/CBT reported good short-term gains in cART adherence but limited efficacy in sustaining adherence improvement and VL reduction at follow-up points [66] [67] [68] . In a RCT of 143 HIV-infected hazardous alcohol drinkers assigned to an eight-session MI/ CBT intervention or a time-and content-equivalent educational condition, participants in the MI/CBT group demonstrated statistical (but not clinically significant) decreases in VL (at least a 0.5 log reduction), significant increases in CD4, and significantly greater improvement in cART adherence at the 3-month follow-up compared to the education condition [66] . None of the outcomes were sustained, however, at the 6-month visit.
Data from two pilot trials are largely consistent with the Parson's 2007 RCT. Improvements in cART adherence were demonstrated for pilot trials incorporating MI plus feedback and skills building and MI/CBT through 3-6 months [67, 68] . These data, however, must be interpreted cautiously as one was an uncontrolled trial [67] and the other reported no significance between-groups effect for cART adherence between the MI and the control video education groups at any time point [68] . Similarly, there were no statistically significant main or between-group effects for the interventions on VL reductions or the proportion of participants with viral suppression.
Nurse-Delivered Multi-component Interventions
Three strong, high quality RCTs have incorporated nursedelivered multi-component interventions [69] [70] [71] . The data from the three trials consistently indicate improvements in viral suppression and cART adherence in the short term, but the benefits do not persist. The interventions were multicomponent, incorporating many different treatment elements that are described below.
Samet et al. [69] conducted an RCT of a multicomponent, nurse-delivered intervention to each participant to promote cART adherence and compared it to routine medical follow-up (including written or oral instructions about optimal medication adherence strategies) among 151 HIV-infected individuals with alcohol use disorders. Nurses trained in MI delivered the intervention over 3 months in four encounters (including a home visit) and included: addressing alcohol problems; providing a watch with a programmable timer to facilitate pill taking; promoting treatment self-efficacy; and delivering individually tailored assistance to facilitate medication use. No significant differences in medication adherence, CD4, or VL were detected after 6 or 12 months.
Results from the Williams et al. [70] and Wang et al. [71] counseling studies are consistent with the Samet et al. [69] trial despite the difference in treatment length and dose/intensity, substance abuse eligibility criteria, and geographical location. The Williams et al. [70] trial evaluated the efficacy of a 1-year home-visit intervention and compared it to usual care among 171 HIV-infected adults. The intervention team, consisting of a nurse and a community support worker, encouraged subjects to identify individual and social factors that they perceived as influencing their success with cART adherence. Usual care was variable and consisted of assistance with the development of medication schedules and strategies to improve adherence and/or patient education regarding medication dose, side effects, and the need for adherence. The proportion achieving >90 % adherence in the intervention group through 15-month follow-up was statistically significant, yet when computed as a continuous variable, there were no differences between the two groups in change in adherence, VL, or CD4 count at 12 and 15 months.
In a replication study, Wang et al. [71] randomized 116 HIV-infected active or past heroin injectors to receive nursedelivered home visits combined with telephone intervention over 8 months in China, while the control group received routine care. The home visits, expanded on in prior work [70] , added semi-structured telephone calls to enforce the home visits. Routine care, however, was not described. After eight months, participants in the experimental group were significantly more likely to self-report taking 100 % adherence, yet the study was limited by lack of virologic or immunologic outcomes.
Social Support and Peer-Driven Interventions
Preliminary peer-driven interventions have suggested some initial promise in fostering improved short-term treatment adherence among HIV-infected stimulant and opioid users [72, 73] . Longer term assessments in RCTs, however, suggest that improvements in adherence delivered through peerdriven or family support interventions may subside or decline over time.
Feaster et al. [74] conducted a RCT comparing Structural Ecosystems Therapy (SET), a 4-month intervention focused on building family support for relapse prevention and HIV medication adherence, to a psychoeducational Health Group (HG) in 126 HIV-infected women in recovery. SET participants, compared to HG, demonstrated no impact on VL, declining medication adherence, but a statistically significant increase in CD4 count at 12 months, primarily related to an increased proportion of SET participants receiving cART.
Purcell et al. [75] compared a ten-session peer mentoring intervention to an eight-session video discussion intervention (control condition) among 966 HIV-infected IDUs recruited in four US cities. Throughout 12-months of observation, there were no differences in adherence between the two conditions at any time point, and biological outcomes were not measured.
Educational Counseling
Educational counseling interventions targeting cART adherence among PWUDs are limited. One 5-month pilot observation study among a sample of primarily HIV-infected African American IDUs with documented cART nonadherence suggested that a brief intervention incorporating medication adherence psychoeducation counseling sessions with multi-compartment weekly pill organizers showed a significant increase in adherence, medication refills, and clinic appointments compared to baseline [76] .
Adherence Case Management (Medication Management, Counseling, Incentives, Electronic Reminder) Data for adherence case management programs are limited. One small community-based program reported that 16 of 25 (64 %) patients receiving cART and case management for at least 2 months exhibited viral suppression, yet neither adherence was reported nor was there a comparison group [77] .
Timer/Reminder Interventions
There are few efficacy data regarding the use of pager or timer-reminder interventions to promote cART adherence among PWUD, though they are suggestive at improving virologic suppression. One small study indicated that although well-accepted by participants and fairly feasible to implement, timer/reminders did not improve cART adherence among HIV-infected illicit drug and alcohol users after 1 and 2 month follow-ups [78] . In another small pilot study for out-of-drug treatment HIV-infected IDUs at mobile healthcare sites, viral suppression was achieved by 85 % at 6 months, 77 % at 9 months, and 54 % by 12 months [79] when adherence was linked to injection practice reminders.
Integrated Medication-Assisted Therapy and Behavioral Interventions
The following section reports on the results of interventions that integrate medication-assisted therapies, such as with methadone or buprenorphine, various behavioral or psychosocial interventions, or other systems of care to improve HIV treatment outcomes. These interventions are limited to one RCT, pilot data, or examination of only adherence or only virologic and immunologic outcomes [31, 80, 81•, 82] .
Integrating Medication-Assisted Therapy with HIV Treatment Trials targeting the integration of medication-assisted therapies into HIV primary care have shown initial promise in improving HIV treatment outcomes. In the only identified RCT, Lucas et al. [80] conducted a 12-month RCT in which clinic-based treatment with buprenorphine and individual counseling was compared to case management and referral to an opioid treatment program among 93 HIV-infected, opioid-dependent subjects. Those with integrated care were significantly more likely to receive substance abuse treatment, but there were no significant changes from baseline in VL and CD4 between the study arms with respect to adherence to cART, VL, and CD4 counts.
In a much larger observational cohort, Altice et al. [81•] reported that longer retention on buprenorphine treatment was significantly associated with increased likelihood of initiating cART, and improving CD4 counts for the entire cohort. It was not, however, associated with improved virological suppression, primarily due to the large proportion already on cART at baseline and high levels of virological suppression. Another study integrating BPN into HIV clinical care settings resulted in increases in initiation of cART and CD4. Among a subset of individuals who were not on cART at baseline, retention on BPN for 6 to 12 months resulted in an increased proportion of subjects with viral suppression compared to those who received BPN for shorter durations. When the analysis was limited to those not on cART at baseline, longer retention on BPN was significantly associated with higher levels of viral suppression compared to those with shorter BPN retention. Small pilot studies integrating BPN into HIV treatment settings suggest improvements in adherence and CD4 and trends in VL improvement at 3 and 6 month follow-up time points for those receiving integrated BPN and HIV care [31, 82] .
Methadone Maintenance and Risk Reduction Counseling Treatment
Margolin et al. [83] randomized 90 HIV-infected IDUs receiving MMT to a 6-month behavioral intervention, the Holistic Health Recovery Project (HHRP+), or to an active enhanced MMT control that included harm reduction components recommended by the National AIDS Demonstration Research Project. Significantly more patients assigned to HHRP+reported >95 % adherence during the study treatment phase than did patients assigned to control group. Virologic changes as a result of the intervention were not examined in the trial.
Methadone Maintenance and CBT/MI Counseling
Safren et al. [84] conducted an RCT of an eight-session CBT intervention that addressed both cART adherence and depression (compared to enhanced control group of 89 opioid dependent, depressed HIV-infected patients receiving MMT). The control group included physician assessments and MEMs cap reading. At the end of treatment, the intervention arm had significantly greater cART adherence and reduction in depression compared to controls. Although depression gains were sustained, neither adherence nor virological outcomes persisted at 6 and 12-months.
Methadone Maintenance and Medication Coaching/Voucher Reinforcement
Sorensen et al. [85] randomized 66 HIV-infected MMT patients to 12 weeks of medication coaching plus voucher reinforcement for opening electronic medication caps on time versus a control of medication coaching only to assist with adherence. Though the intervention resulted in improved adherence, there were no statistically significant effects for either VL or CD4. Consistent with other contingency management trials, the differences in adherence disappeared between the groups when the vouchers were discontinued.
Discussion
The current review was undertaken to provide an updated review of the scientific evidence for interventions that promote cART adherence among HIV-infected PWUDs. Current findings support several cART adherence interventions among PWUDs, including immediate improvements in adherence and virologic suppression. The best data support DAART alone and DAART integrated within MAT programs. Indeed, three strong DAART RCT trials showed evidence for significant VL or CD4 improvements during the intervention period when compared to controls, including when DAART is integrated within MMT [49] [50] [51] . The long-term persistence associated with DAART, however, is not supportive as a stand-alone intervention [52, 53] and likely requires longer-term treatment, transitional programs, or booster sessions. The single arm longitudinal studies support sustained viral suppression and incremental CD4 increases over 12 [58] and 24 [59] months of treatment, yet this suggests that patients may need this level of intervention for a lifetime unless transitional interventions prove effective. Other studies have supported the limited posttreatment effects of DAART [86] .
Although clinically intuitive, DAART interventions are labor-intensive and costly to implement. Although DAART trials have been shown to be cost-effective for various health conditions, including multidrug-resistant tuberculosis [87] , the feasibility of implementing these interventions on a large scale and over a sustained time period is uncertain for lifelong cART regimens. Nevertheless, in settings capable of implementing them, DAART interventions show the strongest intervention effect among non-adherent PWUDs. They have not, however, been studied among cART-naïve patients who have not yet demonstrated non-adherence and may prove beneficial in the short-term for this population. Costeffectiveness analyses need be undertaken to evaluate the fiscal circumstances and cost-benefit ratios in order to optimize the implementation of DAART treatments for HIVinfected populations in various international and domestic regions where resources remain constrained.
Although quite different in theoretical orientation and intervention content, nurse-delivered multi-component interventions and contingency management treatments were not as consistent as DAART interventions, but, overall, resulted in non-sustained benefits in the few trials where an intervention effect was found [63] [64] [65] [69] [70] [71] . By end of treatment and/or follow-up, differences between groups in adherence and viral load were no longer significantly different. Additional research efforts should aim to design contingency management or nurse-delivered multicomponent interventions that extend the adherence and virologic effects of the interventions. In light of the current findings, however, there are insufficient data to fully support multi-component interventions or contingency management as long-term adherence strategies, yet RCTs are currently underway.
Although there are promising data from pilot trials, the efficacy of educational counseling, adherence case management, timer/reminder, peer-driven and family support interventions to promote cART adherence among PWUDs has not been established. For example, although preliminary pilot peer-driven and family support interventions have reported somewhat favorable trends in cART adherence gains [72, 73] , the longer assessment timeframes traditionally captured in RCTs indicated that improvements in adherence as a function of peer-driven or family support interventions gains may subside over time. More conclusive larger-scale trials are needed to evaluate the potency of these interventions.
Though the findings for the integration of MAT into HIV treatment is generally supportive of improving HIV treatment outcomes, RCTs have yet to be fully conducted. Uncontrolled trials consistently showed increases in adherence [42] , likelihood of prescribing cART, viral suppression, and CD4 [47, 82] in individuals receiving MAT. In addition, data supports improvements in cART adherence and stable VL and CD4 at short-term follow-ups among populations treated with BPN [45, 46] and long-term virologic success with retention in OST care [48] . The only RCT [80] to date that evaluated the integration of buprenorphine into HIV clinical care settings did not indicate improvement in cART adherence or virologic and immunologic outcomes, although this is best explained by the high proportion of subjects already prescribed and adherent to cART at baseline.
The degree to which behavioral interventions potentiate the effects of ongoing MAT should be explored further. Three RCTs integrating MMT and various behavioral interventions [83] [84] [85] displayed short-term adherence gains but none support long-term virologic suppression. Additional rigorous trials on the clinical efficacy of integrated MAT and behavioral interventions for cART adherence and relevant HIV clinical outcomes for HIV-infected PWUD populations are urgently needed.
Of great concern is that none of the adherence interventions among PWUDs, in general, demonstrate long-term, post-intervention HIV treatment outcomes. One of the central tenets for the future success of the "seek, test, treat, and retain" and "treatment as prevention" paradigms is to foster and maintain HIV treatment adherence among vulnerable populations, such as PWUDs. Because HIV is a chronic, life-long illness, interventions meant to facilitate durable adherence to cART regimens will likely need to include ongoing booster sessions to promote and maintain adherence behaviors or to initiate them before a patient has entered into significant patterns of non-adherence. Furthermore, interventions that simultaneously target drug abuse as well as non-adherence may provide more long-term success, as attempting to substantively modify adherence patterns in the absence of concomitantly treating drug abuse may be difficult.
An intuitive and unique potential platform for the delivery of ongoing, sustained and long-term HIV adherence care may be through the use of mobile technologies. Given their relative low cost and wide penetration across the US and most international settings, albeit with uncertain acceptability among PWUDs, mobile technologies (e.g., cell phone, smart phones) may offer new opportunities for long-term adherence monitoring and intervention. Future research efforts should focus on evaluating the acceptability, feasibility, clinical efficacy, and cost-effectiveness of technologically-delivered interventions that range the gamut, from those that include elements of CM, CBT, MI, DAART (through video). Various technologies and the applications they support, including short message services, real-time, global positioning system, connectivity to the internet (and educational and social support services) allow for an unprecedented opportunity to provide interventions in "real time" (in response to missed HIV doses, heightened drug cues) and over a longer sustained timeframe (if only to provide booster sessions) than has previously been possible. Future research can also identify subpopulations among PWUDs for whom certain technologies and/or mode of communication with providers or peers may be preferred and/or most efficacious. Multiple potential funding mechanisms within the National Institutes of Health place emphasis on the development and evaluation of these technologicallydelivered interventions for PWUDs (e.g., Program Announcement: PA: 12-117 and 12-118).
Though an exhaustive review of cART adherence interventions was conducted, limitations remain. First, the authors narrowly limited the HIV treatment outcomes to adherence, viral suppression, and immunologic outcomes. Structural interventions, such as changes in drug policy, reducing incarceration or community-based policing, were not empirically tested and therefore not included. Outcomes relating to substance abuse treatment, engagement and retention in care, mortality, and resistance, while important, were not the target of this review. Additionally, although the authors deployed a comprehensive set of search strategies to identify relevant articles, it is possible that the authors overlooked some articles, potentially biasing the interpretations and discussion. Finally, there was no quantification of intervention effects, with this review solely focusing on reporting general trends in the literature. One of the challenges for this review, as noted by others [29•, 88] , is the inconsistency and lack of uniformity in the reporting of important dependent variables across the reviewed studies. For example, past experience with cART regimens was often not elucidated in trials nor was any potential differential effect of interventions on cART-naïve versus cART-experienced participants. Substance abuse disease severity was usually underreported and/or highly heterogeneous across samples, including definitions of abuse versus dependence. Virologic and immunologic markers of disease severity as well as cART rates were often missing at baseline for included samples, so the degree and robustness of any given intervention's effect was difficult to quantify. Moreover, adherence was measured over differing time frames (e.g., daily, past week, month), during differing time periods (e.g., 4, 6, 12 or 24 months) and with various adherence thresholds (mean, >90, >95 %). To the extent possible, a more consistent approach to reporting and data analysis is required in order to make more meaningful inferences across trials.
Conclusion
Recent guidelines, using rigorous techniques for classifying the quality of trials, provide the strongest support for DAART to support cART adherence among PWUDs. Within this review, however, there are a number of other potentially promising options that require further investigation; they should be reassessed with booster sessions, in cART-naïve PWUDs, and subjected to longer-term evaluation. In order to achieve the benefits needed to reduce HIV transmission and effectively reduced HIV-related mortality, such interventions will ultimately need to be efficacious, effective in real-world settings, and result in sustainable viral suppression.
